07-10-2016 10:15 - 11:45 Type: Educational session Vienna Title: Cancer Immunotherapy (CIT): What every oncologist should know Chair(s): I. Melero, ES; S. van der Burg, NL 10:15 - 10:30 Back to the basics S. van der Burg, Leiden, NL 10:30 - 10:55 Cancer vaccines: Can we make them work? C. Melief, Leiden, NL 10:55 - 11:20 T cell therapy: For whom and when? I.-M. Svane, Herlev, DK 11:20 - 11:45 Immune checkpoints: Do we really know how they work? I. Melero, Pamplona, ES Last update: 04-10-2016 03:03:23pm esmo.org 12:00 - 13:20 Type: Opening session Copenhagen Title: Opening Session and Award lectures - Followed by welcome refreshments Chair(s): F. Ciardiello, IT 12:00 - 12:10 ESMO Presidential Address F. Ciardiello, Napoli, IT 12:10 - 12:15 Welcome to Copenhagen U. Lassen, Copenhagen, DK 12:15 - 12:20 ESMO 2016 Scientific address A. Cervantes, Valencia, ES 12:20 - 12:25 Presentation of the ESMO Award by C. Zielinski, Vienna, AT 12:25 - 12:40 ESMO Award lecture: The hard road to ranking the clinical benefit of antineoplastic drugs A. Sobrero, Genoa, IT 12:40 - 12:45 Presentation of the ESMO Hamilton Fairley Award by C. Zielinski, Vienna, AT 12:45 - 13:00 ESMO Hamilton Fairley Award lecture: The new genome driver-based stratification of breast cancer C. Caldas, Cambridge, GB 13:00 - 13:05 Presentation of the ESMO Lifetime Achievement Award by C. Zielinski, Vienna, AT 13:05 - 13:20 ESMO Lifetime Achievement Award lecture R. Peto, Oxford, GB 13:20 - 13:20 Welcome refreshments in the exhibition Last update: 04-10-2016 03:03:23pm esmo.org 14:00 - 15:30 Type: Proffered Paper session Copenhagen Title: Genitourinary tumours, prostate Chair(s): F. Feng, US; G. Attard, GB 14:00 - 14:15 717O - Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP) 1 1 1 1 2 3 4 5 W. Xie , C. Sweeney , M. Regan , M. Nakabayashi , M. Buyse , N. Clarke , L. Collette , J. Dignam , 6 7 8 9 10 11 12 13 K. Fizazi , M. Habibian , S. Halabi , P. Kantoff , W. Parulekar , H. Sandler , O. Sartor , H. Soule 14 4 15 1 2 3 4 , M. Sydes , B. Tombal , S. Williams ; Boston, MA/US, Louvain-La-neuve, BE, Manchester, GB, 5 6 7 8 9 10 11 Brussels, BE, Chicago, US, Villejuif, FR, Paris, FR, Durham, US, New York, US, Kinston, CA, 12 13 14 15 Los Angeles, CA/US, New Orleans, US, Santa Monica, US, London, GB, East Melbourne, AU 14:15 - 14:30 718O - PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) 1 2 3 4 1 5 6 J. de Bono , U. De Giorgi , C. Massard , S. Bracarda , D. Nava Rodrigues , I. Kocak , A. Font , J. 7 8 9 10 11 11 11 1 Arranz Arija , K. Shih , G. Radavoi , W. Yu , W. Chan , S. Gendreau , L. Zhang , R. Riisnaes , 10 11 9 1 2 3 4 5 M. Wongchenko , D. Maslyar , V. Jinga ; London, GB, Meldola, IT, Villejuif, FR, Arezzo, IT, 6 7 8 9 10 Brno, CW, Badalona, ES, Madrid, ES, Nashville, TN/US, Bucharest, RO, South San Francisco, 11 CA/US, South San Francisco, US 14:30 - 14:45 Invited discussant abstracts 717O and 718O F. Feng, Ann Arbor, US 14:45 - 15:00 LBA29 - A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC) 1 2 3 4 5 6 7 H. Beltran , D. Danila , B. Montgomery , R. Szmulewitz , U. Vaishampayan , A. Armstrong , M. Stein , 8 9 1 1 1 1 1 1 C. Hoimes , J. Pinski , H. Scher , L. Puca , R. Bareja , W. Wong , M. Rubin , J.M. Mosquera , A. 1 1 1 1 2 1 2 3 Sboner , C. Oromendia , D. Nanus , K. Ballman , S. Tagawa ; New York, Ny, US, New York, US, 4 5 6 7 8 9 Seattle, US, Chicago, US, Detroit, US, Durham, NC/US, New Brunswick, US, Cleveland, US, Los Angeles, US 15:00 - 15:15 719O - First evidence of significant clinical activity of PD-1 inhibitors in metastatic, castration resistant prostate cancer (mCRPC) 1 1 2 1 3 1 1 1 1 J. Graff , J. Alumkal , C. Drake , G. Thomas , W. Redmond , M. Farhad , R. Slottke , T. Beer ; 2 3 Portland, OR/US, Baltimore, US, Portland, US 15:15 - 15:30 Invited discussant abstracts LBA29 and 719O W. Gerritsen, Nijmegen, NL Last update: 04-10-2016 03:03:23pm esmo.org 14:00 - 15:30 Type: Educational session Vienna Title: Metastatic colorectal cancer: Providing the continuum of care Chair(s): C. Tournigand, FR; C. Qvortrup, DK 14:00 - 14:30 What can be done beyond first line targeted agents: Switch or continue? D. Arnold, Freiburg, DE 14:30 - 15:00 Re-introduction: Is it a valid concept? C. Tournigand, Créteil, FR 15:00 - 15:30 On-treatment biomarkers: Do they help to define the best sequence? C. Montagut, Barcelona, ES 14:00 - 15:30 Type: Educational session Stockholm Title: New developments in the management of ER-positive metastatic breast cancer Chair(s): R. Coleman, GB; G. Curigliano, IT 14:00 - 14:30 Unlocking the pathways of endocrine resistance G. Curigliano, Milan, IT 14:30 - 15:00 Current and emerging treatment approaches: An embarrassment of riches? N. Harbeck, München, DE 15:00 - 15:30 Minimising the toxicities of targeted therapies T. Bachelot, Lyon, FR Last update: 04-10-2016 03:03:23pm esmo.org 14:00 - 15:30 Type: Proffered Paper session Madrid Title: Non-metastatic NSCLC and other thoracic malignancies Chair(s): D. De Ruysscher, NL; P. Garrido, ES 14:00 - 14:15 LBA41_PR - Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer 1 1 2 3 2 2 1 1 P. Forde , K. Smith , J. Chaft , M. Hellmann , T. Merghoub , J. Wolchok , S. Yang , R. Battafarano , 1 1 1 1 1 1 1 E. Gabrielson , C. Georgiades , F. Verde , G. Rosner , J. Naidoo , T. Cottrell , J. Taube , V. 1 1 1 1 1 1 2 Anagnostou , V. Velculescu , S. Topalian , D. Pardoll , J. Brahmer ; Baltimore, MD/US, New York, 3 NY/US, New York, US 14:15 - 14:30 1178O - Multi-centre randomized controlled study comparing adjuvant vs neo-adjuvant chemotherapy with docetaxel plus carboplatin in resectable stage IB to IIIA NSCLC: final results of CSLC0501 1 1 1 1 1 2 3 1 4 Y.-L. Wu , X.-N. Yang , W. Zhong , X. Ben , G.-B. Qiao , Q. Wang , C. Wang , H.-H. Luo , Z. Wang , 1 1 2 3 4 H.-H. Yan ; Guangzhou, CN, Shanghai, CN, Tianjin, CN, Shenzhen, CN 14:30 - 14:45 Invited discussant LBA41 and abstract 1178O P. Baas, Amsterdam, NL 14:45 - 15:00 1423O - Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) +& 1 2 3 4 5 6 7 T. Owonikoko , K. Nackaerts , T. Csoszi , G. Ostoros , C. Baik , Z. Mark , E. Sheldon-Waniga , D. 7 7 8 1 2 3 4 5 Huebner , E.J. Leonard , D. Spigel ; Atlanta, GA/US, Leuven, BE, Szolnok, HU, Budapest, HU, 6 7 8 Seattle, WA/US, Törökbálint, HU, Cambridge, MA/US, Nashville, TN/US 15:00 - 15:15 1424O - Small cell lung carcinoma harbors targetable alterations including MYCL1 fusions responding to aurora kinase inhibitor 1 2 1 3 4 3 1 5 1 S. Ali , B. Kolla , M. Bailey , A. Schrock , S. Klempner , G. Frampton , D. Fabrizio , S.-H. Ou , J. He , 1 6 1 1 2 1 2 3 J. Suh , J. Ross , P. Stephens , V. Miller , M. Patel ; Cambridge, MA/US, Minneapolis, US, 4 5 6 Cambridge, US, Los Angeles, US, Irvine, CA/US, Albany, NY/US 15:15 - 15:30 Invited discussant abstracts 1423O and 1424O P. Garrido Lopez, Madrid, ES Last update: 04-10-2016 03:03:23pm esmo.org 14:00 - 15:30 Type: Proffered Paper session Oslo Title: Gynaecological cancers Chair(s): A. Poveda, ES; C. Sessa, CH 14:00 - 14:15 854O - Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers 1 2 3 4 1 2 I. Vergote , B. Lund , H. Havsteen , Z. Ujmajuridze , E. Van Nieuwenhuysen , C. Haslund , T. 4 1 4 1 5 6 6 Juhler-Nøttrup , P. Neven , M. Mau-Sørensen , P. Berteloot , A. Kranich , T. Rashal , J. Meade , Y. 6 7 6 6 6 6 Landesman , J.-R. Saint-Martin , G. Wright , M. Crochiere , S. Shacham , M. Kauffman , M. Raza 6 1 2 3 4 5 6 Mirza ; Leuven, BE, Aalborg, DK, Herlev, DK, Copenhagen, DK, Hamburg, DE, Newton, MA/US, 7 Natick, US 14:15 - 14:30 855O - A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm+ OvCa) J.-M. Lee, F. Karzai, A. Zimmer, C. Annunziata, S. Lipkowitz, B. Parker, N. Houston, I. Ekwede, E. Kohn; Rockville, US 14:30 - 14:45 Invited discussant abstract 854O and 855O C. Gourley, Edinburgh, GB 14:45 - 15:00 856O - Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2) 1 2 3 3 4 5 R. Kristeleit , R.